Drug Profile
Hib-DTaP-Hepatitis-B-Poliovirus-vaccine - Merck
Alternative Names: DTaP5-HepB-Polio-Hib - Merck; DTP-HepB-Polio-Hib vaccine - Merck; Pediatric hexavalent vaccine; Pediatric hexavalent vaccine PR5i; PR5I; V419; VaxelisLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co; sanofi pasteur
- Developer Merck & Co; Sanofi
- Class Haemophilus vaccines; Hepatitis B vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus